目的：本研究评估了大剂量维生素D补充剂在减轻COVID后综合征患者疲劳和神经精神症状方面的有效性。
方法：在8周内，双盲,随机化，安慰剂对照试验,纳入80例COVID后疲劳或神经精神症状患者。参与者被随机分配每周接受60,000IU维生素D（n=40）或安慰剂（n=40），为期8周。使用11项Chalder疲劳量表（CFQ-11）评估临床结果；21项抑郁症，焦虑,和压力量表（DASS-21）；匹兹堡睡眠质量指数（PSQI）；Addenbrooke的认知检查III（ACE）；以及跟踪测试A和B（TMT-A和TMT-B）。炎症标志物的基线和8周测量，包括白细胞介素6（IL-6）和C反应蛋白（CRP），也被收集了。
结果：发现维生素D组对CFQ的显着改善（系数-3.5，P=0.024），DASS焦虑（-2.0，P=0.011），和ACE（2.1，P=0.012）。在PSQI中没有观察到显著差异,DASS-抑郁,TMT,IL-6或CRP水平。两组之间的不良事件发生率相当，未报告严重不良事件。
结论：大剂量补充维生素D可能通过减轻疲劳使COVID后综合征患者受益，缓解焦虑,改善认知症状，副作用最小。
OBJECTIVE: This
study evaluated the effectiveness of high-dose vitamin D supplementation in alleviating fatigue and neuropsychiatric symptoms in post-COVID syndrome.
METHODS: In an 8-week, double-blind, randomized, placebo-controlled
trial, 80 patients with post-COVID fatigue or neuropsychiatric symptoms were enrolled. Participants were randomly assigned to receive either 60,000 IU of vitamin D weekly (n = 40) or a placebo (n = 40) for 8 weeks. Clinical outcomes were assessed using the 11-item Chalder Fatigue Scale (CFQ-11); 21-item Depression, Anxiety, and Stress Scale (DASS-21); Pittsburgh Sleep Quality Index (PSQI); Addenbrooke\'s Cognitive Examination III (ACE); and Trail Making Test A and B (TMT-A and TMT-B). Baseline and 8-week measurements of inflammatory markers, including interleukin 6 (IL-6) and C-reactive protein (CRP), were also collected.
RESULTS: Significant improvements were found in the vitamin D group for CFQ (coefficient -3.5, P = 0.024), DASS-anxiety (-2.0, P = 0.011), and ACE (2.1, P = 0.012). No significant differences were observed in PSQI, DASS-depression, TMT, IL-6, or CRP levels. The incidence of adverse events was comparable between groups, with no serious adverse events reported.
CONCLUSIONS: High-dose vitamin D supplementation may benefit patients with post-COVID syndrome by reducing fatigue, alleviating anxiety, and improving cognitive symptoms, with minimal side effects.
